RATIONALE: Bacterial pneumonia is the most common infectious cause of death worldwide and treatment is increasingly hampered by antibiotic resistance. Mesenchymal stem cells (MSCs) have been demonstrated to provide protection against acute inflammatory lung injury; however, their potential therapeutic role in the setting of bacterial pneumonia has not been well studied. OBJECTIVE: This study focused on testing the therapeutic and mechanistic effects of MSCs in a mouse model of Gram-negative pneumonia. METHODS AND RESULTS: Syngeneic MSCs from wild-type mice were isolated and administered via the intratracheal route to mice 4 h after the mice were infected with Escherichia coli. 3T3 fibroblasts and phosphate-buffered saline (PBS) were used as controls for all in vivo experiments. Survival, lung injury, bacterial counts and indices of inflammation were measured in each treatment group. Treatment with wild-type MSCs improved 48 h survival (MSC, 55%; 3T3, 8%; PBS, 0%; p<0.05 for MSC vs 3T3 and PBS groups) and lung injury compared with control mice. In addition, wild-type MSCs enhanced bacterial clearance from the alveolar space as early as 4 h after administration, an effect that was not observed with the other treatment groups. The antibacterial effect with MSCs was due, in part, to their upregulation of the antibacterial protein lipocalin 2. CONCLUSIONS: Treatment with MSCs enhanced survival and bacterial clearance in a mouse model of Gram-negative pneumonia. The bacterial clearance effect was due, in part, to the upregulation of lipocalin 2 production by MSCs.
RATIONALE: Bacterial pneumonia is the most common infectious cause of death worldwide and treatment is increasingly hampered by antibiotic resistance. Mesenchymal stem cells (MSCs) have been demonstrated to provide protection against acute inflammatory lung injury; however, their potential therapeutic role in the setting of bacterial pneumonia has not been well studied. OBJECTIVE: This study focused on testing the therapeutic and mechanistic effects of MSCs in a mouse model of Gram-negative pneumonia. METHODS AND RESULTS: Syngeneic MSCs from wild-type mice were isolated and administered via the intratracheal route to mice 4 h after the mice were infected with Escherichia coli. 3T3 fibroblasts and phosphate-buffered saline (PBS) were used as controls for all in vivo experiments. Survival, lung injury, bacterial counts and indices of inflammation were measured in each treatment group. Treatment with wild-type MSCs improved 48 h survival (MSC, 55%; 3T3, 8%; PBS, 0%; p<0.05 for MSC vs 3T3 and PBS groups) and lung injury compared with control mice. In addition, wild-type MSCs enhanced bacterial clearance from the alveolar space as early as 4 h after administration, an effect that was not observed with the other treatment groups. The antibacterial effect with MSCs was due, in part, to their upregulation of the antibacterial protein lipocalin 2. CONCLUSIONS: Treatment with MSCs enhanced survival and bacterial clearance in a mouse model of Gram-negative pneumonia. The bacterial clearance effect was due, in part, to the upregulation of lipocalin 2 production by MSCs.
Authors: Jae W Lee; Xiaohui Fang; Naveen Gupta; Vladimir Serikov; Michael A Matthay Journal: Proc Natl Acad Sci U S A Date: 2009-08-31 Impact factor: 11.205
Authors: Michael A Bachman; Jennifer E Oyler; Samuel H Burns; Mélissa Caza; François Lépine; Charles M Dozois; Jeffrey N Weiser Journal: Infect Immun Date: 2011-05-16 Impact factor: 3.441
Authors: M D Eisner; T Thompson; L D Hudson; J M Luce; D Hayden; D Schoenfeld; M A Matthay Journal: Am J Respir Crit Care Med Date: 2001-07-15 Impact factor: 21.405
Authors: Shirley H J Mei; Jack J Haitsma; Claudia C Dos Santos; Yupu Deng; Patrick F H Lai; Arthur S Slutsky; W Conrad Liles; Duncan J Stewart Journal: Am J Respir Crit Care Med Date: 2010-06-17 Impact factor: 21.405
Authors: Hong Wu; Eric Santoni-Rugiu; Elisabeth Ralfkiaer; Bo T Porse; Claus Moser; Niels Høiby; Niels Borregaard; Jack B Cowland Journal: Respir Res Date: 2010-07-15
Authors: Yvonne R Chan; Jessica S Liu; Derek A Pociask; Mingquan Zheng; Timothy A Mietzner; Thorsten Berger; Tak W Mak; Matthew C Clifton; Roland K Strong; Prabir Ray; Jay K Kolls Journal: J Immunol Date: 2009-04-15 Impact factor: 5.422
Authors: A Balan; G Lucchini; S Schmidt; A Schneider; L Tramsen; S Kuçi; R Meisel; P Bader; T Lehrnbecher Journal: Leukemia Date: 2014-04-03 Impact factor: 11.528
Authors: Daniel J Weiss; Daniel Chambers; Adam Giangreco; Armand Keating; Darrell Kotton; Peter I Lelkes; Darcy E Wagner; Darwin J Prockop Journal: Ann Am Thorac Soc Date: 2015-04
Authors: Oscar E Simonson; Dimitrios Mougiakakos; Nina Heldring; Giulio Bassi; Henrik J Johansson; Magnus Dalén; Regina Jitschin; Sergey Rodin; Matthias Corbascio; Samir El Andaloussi; Oscar P B Wiklander; Joel Z Nordin; Johan Skog; Charlotte Romain; Tina Koestler; Laila Hellgren-Johansson; Petter Schiller; Per-Olof Joachimsson; Hans Hägglund; Mattias Mattsson; Janne Lehtiö; Omid R Faridani; Rickard Sandberg; Olle Korsgren; Mauro Krampera; Daniel J Weiss; Karl-Henrik Grinnemo; Katarina Le Blanc Journal: Stem Cells Transl Med Date: 2015-08-18 Impact factor: 6.940